股票代码：688505 股票简称：复旦张江 公告编号：临 2025-005 上海复旦张江生物医药股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 3 月 21 日（周五）至 3 月 27 日（周四）16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@fd-zj.com 进行 提问。公司将在说明会上对投资者普遍关注的问题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）将于 2025 年 3 月 28 日于上海证券交易所网站（www.sse.com.cn）披露《上海复旦张江生物医药股 份有限公司 2024 年年度报告》。为便于广大投资者全面深入地了解公司 2024 年 度经营成果、财务状况及发展理念，公司计划于 2025 年 3 月 28 日下午 14:00-15:00 举行 2024 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 三、参加人员 董 事 长、执行董事、总 ...

股票代码：688505 股票简称：复旦张江 编号：临 2025-004 上海复旦张江生物医药股份有限公司 自愿披露关于盐酸氨酮戊酸颗粒剂用于膀胱癌手术可视化 本公司于 2024 年获得该药物研究的临床试验批准通知书。该药物研究旨在 评价膀胱癌患者口服盐酸氨酮戊酸颗粒剂用于荧光引导下肿瘤切除术的有效性 和安全性。截至本公告披露日，该药物研究已完成首例受试者入组。待本临床试 验完成后，根据相关法律法规，可提交该药物的上市申请。 三、 风险提示 由于医药产品具有高科技、高风险、高附加值的特点，药品从临床前研究、 临床试验到商业化的周期长、环节多，容易受到一些不确定性因素的影响。敬请 1 / 2 广大投资者谨慎决策，注意防范投资风险。 验证性临床试验完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）研发的盐酸氨酮戊 酸颗粒剂（以下简称"该药物"）用于非肌层浸润性膀胱癌手术切除辅助的验证 性临床研究于近日成功完成首例受试者入组。 一、 药物的相关情况 膀胱癌 ...

减持股份结果公告 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-003 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划时间届满暨 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海复旦张江生物医药股份有限公司（以下简称"公 司"或"复旦张江"）股东杨宗孟先生持有公司股份 80,000,000 股，占公司总股本 的 7.72%；王海波先生持有公司股份 57,886,430 股，占公司总股本的 5.58%。上 述股东所持有的公司股份来源为公司首次公开发行前持有的股份数量，该部分股 份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 集中竞价减持计划的实施结果情况 1、2024 年 11 月 15 日，公司于上海证券交易所网站（www.sse.com.cn）披 露了《关于持股 5%以上股东减持股份计划公告》（公告编号：临 2024-036）。因 自身资金需求，杨宗孟先生计划通过集中竞价交易的方式减持公 ...

Financial Performance - Total revenue for 2024 was RMB 709.40 million, a decrease of 16.61% compared to RMB 850.73 million in the previous year[4] - Operating profit fell to RMB 2.39 million, down 97.53% from RMB 97.09 million year-on-year[4] - Net profit attributable to shareholders was RMB 39.73 million, a decline of 63.42% from RMB 108.63 million in the previous year[4] - Basic earnings per share decreased to RMB 0.04, down 63.64% from RMB 0.11 in the previous year[4] Research and Development - R&D expenses increased significantly, with an additional RMB 70 million compared to the previous year, driven by the advancement of multiple R&D projects[6] - The FDA018 antibody-drug conjugate project entered Phase III clinical trials, with over 40 clinical trial centers initiated[5] - The FZ-AD005 antibody-drug conjugate project entered Phase I clinical trials, with the first patient enrolled in July 2024[5] Assets and Equity - The company’s total assets decreased by 10.09% to RMB 2.59 billion from RMB 2.88 billion at the beginning of the reporting period[4] - The company’s equity attributable to shareholders decreased by 2.25% to RMB 2.30 billion from RMB 2.36 billion at the beginning of the reporting period[4] Sales and Revenue Impact - The company’s main product sales declined due to the termination of cooperation with a promotional service provider, impacting overall revenue[5]

Financial Performance Forecast - The company expects a net profit attributable to shareholders of RMB 35 million to RMB 52 million for the year 2024, representing a decrease of RMB 56.63 million to RMB 73.63 million, or a decline of 52.13% to 67.78% compared to the previous year[3]. - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between RMB -2 million and RMB 17 million, a decrease of RMB 52.89 million to RMB 71.89 million, or a decline of 75.68% to 102.86% year-over-year[3]. - In the previous year, the net profit attributable to shareholders was RMB 108.63 million, with a total profit of RMB 97.53 million[4]. - The company emphasizes that the performance forecast is based on preliminary calculations and has not been audited by certified public accountants[6]. - Investors are advised to exercise caution and consider the preliminary nature of the forecast data until the audited annual report is released[7]. Research and Development - The company has significantly increased its R&D expenses, with an increase of approximately RMB 70 million compared to the previous year, driven by the advancement of multiple R&D projects[5]. - The FDA018 antibody-drug conjugate project has entered Phase III clinical trials, with over 40 clinical trial centers initiated and the first patient enrolled in August 2024[5]. - The FZ-AD005 antibody-drug conjugate project has entered Phase I clinical trials, with the first patient enrolled in July 2024[5]. - The company's wholly-owned subsidiary has officially started operations at a new ADC production facility and successfully scaled up production processes for two ADC projects[5].

股票代码：688505 股票简称：复旦张江 编号：临 2024-037 上海复旦张江生物医药股份有限公司 二、 补助的类型及对公司的影响 根据《企业会计准则第16号——政府补助》等有关规定，公司上述获得的政 府补助属于与收益相关的政府补助。上述政府补助数据未经审计，具体的会计处 理以及对公司损益的影响，最终以审计机构年度审计确认后的结果为准。敬请投 资者注意投资风险。 特此公告。 上海复旦张江生物医药股份有限公司 董 事 会 二〇二四年十二月三十一日 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 获得补助的基本情况 上海复旦张江生物医药股份有限公司（以下简称"公司"）及公司子公司泰州 复旦张江药业有限公司（以下简称"泰州复旦张江"）、上海溯源生物技术有限公 司自年初至本公告披露日累计收到政府补助资金人民币 3,113.63 万元。上述金额 包含公司子公司泰州复旦张江自年初至 2024 年 6 月 18 日累计收到的政府补助 资金人民币 1,620.00 万元，相关内容详见公司 2024 年 ...

上海复旦张江生物医药股份有限公司 公司代码：688505 公司简称：复旦张江 编号：2024-002 投资者关系活动记录表 上海复旦张江生物医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|----------------------------|------------------------------------------------------| | | | | | | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | 类别 | | □现场参观 □一对一沟通 | | | □ 其他（电话会议） | | | 参与单位名称 | | 深圳青朴资本、太平洋证券、上海晶睿正和投资 | | | 兴业证券策略会 | | | 时间 | 2024 年 12 月 18 | 日 | | 地点 | 2024 年 12 月 20 | 日 公司会议室、上海国际会议中心 | | 公司接待人员姓名 | 投资者关系经理方吟辰女士 | | | 投资者关系活动 | | | | ...

重要内容提示： 大股东持股的基本情况 证券代码：688505 证券简称：复旦张江 公告编号：临 2024-036 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 1 上述减持主体无一致行动人。 大股东上市以来未减持公司股份。 | 股东名 | 计划减持数量 | | 计划减 | | | | 减持合 | 拟减持 | | 拟减 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | （股） | | 持比例 | 减持方式 | | 减持期间 | 理价格 | 股份来 | | 持原 | | | | | | | | | 区间 | 源 | | 因 | | 杨宗孟 | 不超过： | | 不超过： | 竞价交易减 | | 2024/12/6～ | 按市场 | IPO | 前 | 自身 资金 | | | 10,365,721 | 股 | 1% | 持，不超过： | | ...

股票代码：688505 股票简称：复旦张江 编号：临 2024-035 上海复旦张江生物医药股份有限公司 自愿披露关于奥贝胆酸片用于治疗原发性胆汁性胆管炎 药品上市申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）全资子公司泰州 复旦张江药业有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 下发的关于奥贝胆酸片（规格：5mg、10mg）（以下简称"该药品"）用于治疗原 发性胆汁性胆管炎（PBC）的境内生产药品注册上市许可申请的《受理通知书》， 现将相关情况公告如下： 一、 药品的基本情况 申请事项：境内生产药品注册上市许可 受 理 号：CYHS2403676、CYHS2403677 申 请 人：泰州复旦张江药业有限公司 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 二、 药品的其他情况 该药品属于法尼酯 X 受体（Farnesoid X receptor，FXR）激动剂，FXR 是一 种在肝脏和肠道中 ...

Financial Performance - The company's operating revenue for the third quarter was ¥140,724,701, a decrease of 23.99% compared to the same period last year, and a year-to-date revenue of ¥548,848,564, down 22.47% year-on-year[2]. - The net profit attributable to shareholders for the third quarter was ¥15,995,540, a decline of 25.44%, with a year-to-date net profit of ¥86,468,604, down 3.81% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for the third quarter was ¥10,822,388, a decrease of 34.74%, with a year-to-date figure of ¥54,500,468, down 23.76% year-on-year[2]. - Total operating revenue for the first three quarters of 2024 was RMB 548,848,564, a decrease of 22.5% compared to RMB 707,960,683 in the same period of 2023[16]. - Net profit for the first three quarters of 2024 was RMB 86,171,568, a slight decrease of 4.6% compared to RMB 89,811,290 in the same period of 2023[17]. - Basic and diluted earnings per share for the first three quarters were both RMB 0.08, down from RMB 0.09 in the previous year[18]. Research and Development - Research and development (R&D) expenses totaled ¥79,540,074 for the third quarter, an increase of 56.79%, with year-to-date R&D expenses of ¥234,870,223, up 38.71% year-on-year[4]. - The ratio of R&D expenses to operating revenue was 56.52% for the third quarter, an increase of 29.12 percentage points, and 42.79% year-to-date, up 18.87 percentage points year-on-year[4]. - Research and development expenses increased significantly to RMB 235,745,108, up 40% from RMB 168,541,486 in the previous year[16]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥60,152,607, a significant decrease of 3,613.16% year-on-year[4]. - Cash flow from operating activities showed a net outflow of RMB 60,152,607, contrasting with a net inflow of RMB 1,712,208 in the same period last year[20]. - The net increase in cash and cash equivalents was -157,352,803, compared to -46,840,367 in the previous period[21]. - The ending balance of cash and cash equivalents was 1,038,543,194, down from 1,242,462,297 in the previous period[21]. - The company paid 91,127,687 in dividends and interest, an increase from 74,615,047 in the previous period[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,627,120,117, a decrease of 8.68% compared to the end of the previous year[4]. - The company's current assets totaled RMB 1,656,774,707, down from RMB 1,869,424,886, indicating a decrease of about 11.35%[13]. - Total liabilities decreased to RMB 274,499,573 from RMB 518,124,139, a significant reduction of about 47.14%[14]. - The company's equity attributable to shareholders was RMB 2,351,908,069, slightly down from RMB 2,357,553,851, a decrease of about 0.24%[14]. Shareholder Information - The company has a total of 20,006 shareholders, with 19,870 holding A shares and 136 holding H shares[11]. - The largest shareholder, Shanghai Pharmaceutical Group Co., Ltd., holds a total of 210,142,560 shares, including 139,578,560 A shares and 70,564,000 H shares[11]. Other Financial Metrics - The weighted average return on net assets was 0.68%, a decrease of 0.24 percentage points for the quarter, and 3.66% year-to-date, down 0.25 percentage points[4]. - Total operating costs decreased to RMB 490,043,765, down 18.4% from RMB 600,143,402 year-on-year[16]. - Sales expenses decreased to RMB 173,777,581, down 47.9% from RMB 333,644,772 year-on-year[16]. - Tax expenses increased to RMB 5,299,582, compared to RMB 3,893,911 in the same period of 2023[16]. - Other comprehensive income after tax showed a loss of RMB 222,673, compared to a loss of RMB 164,801 in the previous year[18]. Investment Activities - Total cash inflow from investment activities was RMB 3,069,165,185, slightly up from RMB 3,056,147,909 in the previous year[20]. - The company reported a total cash outflow from investing activities of 3,091,638,335, compared to 3,068,186,518 in the previous period[21]. - Cash flow from investing activities totaled 3,068,186,518, with a net cash flow of 978,667, compared to a negative cash flow of 35,490,426 in the previous period[21]. Accounting Standards - The company is not applying the new accounting standards for the current reporting period[22].